Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART2219.1 for Relapsed/Refractory B-Lineage Leukaemia
NCT05429905Phase 2Recruiting
- Sponsor
- KK Women's and Children's Hospital
- Start
- Jul 2022
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of MB-CART2219.1 in acute lymphoblastic leukemia (ALL) (3 cohorts), sponsored by KK Women's and Children's Hospital. Primary endpoints: Recommended Phase II Dose at 30 days, Dose-Limiting Toxicities at 30 days and 1 more. Started Jul 2022; status: recruiting.
02
Drugs
MB-CART2219.1
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05429905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429905.